Related Experiment Video
Updated: Jul 17, 2026
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Efficacy and Safety of Riociguat in Early Pulmonary Vascular Disease: A Prospective, Multicenter, Randomized,
Panagiota Xanthouli1, Nicola Benjamin2, Gerry Coghlan3
1Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital and Translational Lung Research Centre Heidelberg (TLRC), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany; Department of Internal Medicine V: Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Background:
Pulmonary arterial hypertension therapies have not been systematically studied in early disease stages, despite potential benefit.
Research Question:
Is riociguat safe, well tolerated, and potentially effective in early pulmonary vascular disease?
Study Design And Methods:
This was a prospective, multicenter, double-blind phase 2a trial. Adults with early pulmonary vascular disease, defined as mean pulmonary arterial pressure ≥ 25 mm Hg with pulmonary vascular resistance (PVR) ≥ 2 to < 3 Wood units (WU), or mean pulmonary arterial pressure 21 to < 25 mm Hg with PVR ≥ 2 WU, were randomized to receive 1:1 riociguat or placebo for 24 weeks. The primary end point was change in PVR from baseline to week 24. Secondary end points, evaluated hierarchically, comprised changes in cardiac index, total pulmonary resistance, diffusing capacity of the lung for carbon monoxide, 6-minute walking distance, World Health Organization functional class, and quality of life. Complementary parameters were analyzed in an exploratory manner, and safety was monitored throughout.
Results:
Of 261 prescreened patients, 35 eligible patients were randomized to treatment (97% female; mean age, 65.5 ± 6.9 years; 77.1% connective tissue disease-associated pulmonary arterial hypertension); 32 completed the trial. Reasons for ineligibility were documented. Riociguat significantly improved the primary end point of change in PVR (riociguat -0.73 ± 0.67 WU vs placebo -0.02 ± 0.67 WU; P = .043; 27% placebo-adjusted reduction). No significant differences were observed in secondary end points. Of the exploratory end points, only cardiac output showed a trend toward improvement under riociguat (0.35 ± 0.86 L/min vs placebo -0.19 ± 0.75 L/min; P = .084). Only mild to moderate adverse events were observed, and serious events were not considered treatment related.
Interpretation:
Despite the limited number of participants, treatment with riociguat was safe and significantly improved the primary end point PVR over 24 weeks.
Clinical Trial Registration:
ClinicalTrials.gov; No.: NCT05339087; URL: www.
Clinicaltrials:
gov).
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...